Reimagining Medicine
Company overview
Financial review
2023 priorities
Appendix
Continuing core margin improvements for Group driven by IM
Innovative Medicines
Sandoz
Group
Q4 2022
Core operating
FY 2022
Core operating
FINANCIAL PROFILE
Net sales
change vs. PY
income
change vs. PY
Core margin
Core margin
change vs. PY
Net sales
change vs. PY
Core margin
income
change vs. PY
Core margin
change vs. PY
(in % cc)1
(in % cc) 1
(%)1
(%pts cc)1
(in % cc)1
(in % cc)1
(%) 1
(%pts cc)1
3
14
36.4
3.5
4
8
36.9
1.3
0
-18
16.8
-3.8
4
-1
20.6
-1.1
3
15
31.8
3.5
4
8
33.0
1.3
IM - Innovative Medicines. 1. Constant currencies (cc), core results are non-IFRS measures. An explanation of non-IFRS measures can be found on page 49 of the Condensed Interim Financial Report.
39 Investor Relations | Q4 2022 Results
ā NOVARTIS | Reimagining MedicineView entire presentation